Table 2.
RBD-specific antibodies, % inhibition, and seroconversion rate against WT-SARS-CoV-2.
| Time point | Anti-spike RBD (BAU/mL) (median, IQR) | P-value | % Inhibition (median, IQR) | P-value | Seroconversion rate (n, %) | P-value | |||
|---|---|---|---|---|---|---|---|---|---|
| AZD1222 | BNT162b2 | AZD1222 | BNT162b2 | AZD1222 | BNT162b2 | ||||
| Overall | |||||||||
| Before the 3rd dose | 54.0 (46.3, 63.1) | 46.5 (40.2, 53.7) | 0.161 | 32.8 (19.6, 49.5) | 21.3 (9.3, 33.7) | < 0.001 | 79 (57.2) | 44 (31.9) | < 0.001 |
| 4-week after the 3rd dose | 1177.5 (1056.1, 1312.8) | 2863.8 (2600.9, 3153.1) | < 0.001 | 98.3 (97.5, 98.5) | 98.6 (98.4, 98.6) | < 0.001 | 136 (98.6) | 137 (99.3) | 1.000 |
| Before the 4th dose | 249.4 (212.5, 292.7) | 365.5 (312.7, 427.2) | 0.001 | 87.5 (64.3, 95.7) | 94.0 (85.1, 98.0) | < 0.001 | 90 (97.8) | 91 (98.9) | 1.000 |
| 4-week after the 4th dose | 5121.7 (4640.1, 5653.3) | 2835.8 (2536.5, 3170.6) | < 0.001 | 98.2 (98.0, 98.3) | 98.2 (97.9, 98.3) | 0.514 | 89 (98.9) | 91 (100.0) | 0.497 |
| Duration from the 2nd dose ≤ 90 days | |||||||||
| Before the 3rd dose | 80.0 (68.6, 93.4) | 67.5 (59.2, 77.1) | 0.987 | 38.0 (23.5, 52.7) | 28.4 (17.7, 44.7) | 0.008 | 61 (67.8) | 40 (44.4) | 0.002 |
| 4-week after the 3rd dose | 1131.4 (997.3, 1283.5) | 2644.2 (2362.5, 2959.6) | < 0.001 | 98.3 (97.4, 98.5) | 98.6 (98.4, 98.6) | < 0.001 | 90 (100.0) | 90 (100.0) | - |
| Before the 4th dose | 224.9 (186.5, 271.2) | 300.4 (254.2, 355.1) | 0.023 | 86.4 (61.2, 95.7) | 91.9 (83.0, 96.6) | 0.018 | 60 (98.4) | 56 (98.2) | 1.000 |
| 4-week after the 4th dose | 5097.7 (4496.4, 5779.3) | 2857.4 (2438.8, 3347.9) | < 0.001 | 98.2 (97.9, 98.3) | 98.2 (98.0, 98.3) | 0.362 | 60 (100.0) | 57 (100.0) | - |
| Duration from the 2nd dose > 90 days | |||||||||
| Before the 3rd dose | 25.9 (20.6, 32.5) | 23.1 (18.3, 29.0) | 0.474 | 22.2 (17.5, 34.2) | 8.2 (1.1, 19.2) | <0.001 | 18 (37.5) | 4 (8.3) | 0.002 |
| 4-week after the 3rd dose | 1269.1 (1028.9, 1565.3) | 3325.7 (2787.1, 3968.4) | < 0.001 | 98.4 (97.7, 98.6) | 98.6 (98.5, 98.6) | <0.001 | 47 (97.9) | 48 (100.0) | 1.000 |
| Before the 4th dose | 305.6 (225.9, 413.5) | 502.9 (377.5, 670.0) | 0.018 | 88.5 (70.5, 95.7) | 97.6 (90.2, 98.2) | 0.001 | 30 (96.8) | 35 (100.0) | 0.470 |
| 4-week after the 4th dose | 5170.1 (4371.4, 6114.8) | 2800.1 (2417.2, 3243.6) | < 0.001 | 98.2 (98.1, 98.3) | 98.2 (97.8, 98.3) | 0.904 | 29 (96.7) | 34 (100.0) | 0.469 |
The number of participants for AZD1222 was 138 before and after the third dose, 92 before the fourth dose and 90 after the fourth dose. The number of participants for BNT162b2 was 138 before and after the third doses, 92 before the fourth dose and 91 after the fourth dose.